(0.48%) 5 212.50 points
(0.81%) 39 371 points
(0.34%) 16 358 points
(0.58%) $79.45
(5.26%) $2.30
(0.92%) $2 343.70
(3.01%) $28.43
(0.98%) $994.25
(-0.28%) $0.928
(-0.32%) $10.86
(-0.20%) $0.799
(0.87%) $92.54
Live Chart Being Loaded With Signals
Krebs Biochemicals & Industries Limited manufactures and sells active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry fields...
Stats | |
---|---|
Today's Volume | 3 909.00 |
Average Volume | 13 174.00 |
Market Cap | 1.48B |
EPS | INR0 ( 2024-02-11 ) |
Next earnings date | ( INR0 ) 2024-05-21 |
Last Dividend | INR2.90 ( 2005-09-14 ) |
Next Dividend | INR0 ( N/A ) |
P/E | -7.22 |
ATR14 | INR0.666 (0.97%) |
Volume Correlation
Krebs Biochemicals & Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Krebs Biochemicals & Correlation - Currency/Commodity
Krebs Biochemicals & Financials
Annual | 2022 |
Revenue: | INR521.34M |
Gross Profit: | INR264.57M (50.75 %) |
EPS: | INR-11.45 |
FY | 2022 |
Revenue: | INR521.34M |
Gross Profit: | INR264.57M (50.75 %) |
EPS: | INR-11.45 |
FY | 2022 |
Revenue: | INR529.41M |
Gross Profit: | INR-207.59M (-39.21 %) |
EPS: | INR-20.74 |
FY | 2021 |
Revenue: | INR386.06M |
Gross Profit: | INR-136.26M (-35.29 %) |
EPS: | INR-14.53 |
Financial Reports:
No articles found.
Krebs Biochemicals & Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
First Dividend | INR2.90 | 2005-09-14 |
Last Dividend | INR2.90 | 2005-09-14 |
Next Dividend | INR0 | N/A |
Payout Date | 2005-10-01 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | INR2.90 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.38 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 3.18 | |
Div. Directional Score | 1.227 | -- |
Year | Amount | Yield |
---|---|---|
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0 | 0.00% |
2019 | INR0 | 0.00% |
2020 | INR0 | 0.00% |
2021 | INR0 | 0.00% |
2022 | INR0 | 0.00% |
2023 | INR0 | 0.00% |
2024 | INR0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TFCILTD.NS | Dividend Junior | 2023-08-11 | Annually | 23 | 1.38% | |
ORICONENT.NS | Dividend Junior | 2023-09-13 | Annually | 10 | 1.41% | |
IPL.NS | Dividend Junior | 2023-08-17 | Semi-Annually | 3 | 0.18% | |
CREST.NS | Dividend Junior | 2023-08-17 | Annually | 18 | 0.30% | |
SHIVALIK.NS | Dividend Junior | 2023-09-22 | Annually | 3 | 0.03% | |
MANINDS.NS | Dividend Junior | 2023-08-14 | Annually | 20 | 1.51% | |
GRASIM.NS | Dividend Junior | 2023-08-11 | Annually | 23 | 0.31% | |
BAJAJFINSV.NS | Dividend Junior | 2023-06-29 | Annually | 17 | 0.03% | |
UBL.NS | Dividend Junior | 2023-08-03 | Annually | 17 | 0.27% | |
POKARNA.NS | Dividend Junior | 2023-09-11 | Annually | 9 | 0.19% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.417 | 1.500 | -8.34 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.200 | 1.500 | 8.88 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | -3.69 | 1.000 | -2.48 | -2.48 | [3 - 30] |
operatingCashFlowPerShareTTM | 6.10 | 2.00 | 7.97 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 6.10 | 2.00 | 6.95 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.739 | 1.000 | 1.015 | 1.015 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.329 | 1.000 | -8.57 | -8.57 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | -0.725 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -7.31 | 1.000 | -0.839 | 0 | [1 - 100] |
returnOnEquityTTM | 0.200 | 2.50 | 9.28 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 6.10 | 2.00 | 7.97 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 6.10 | 2.00 | 7.97 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.170 | 1.500 | -2.20 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.263 | 1.000 | 5.91 | 0 | [0.1 - 0.5] |
Total Score | 3.18 |
Krebs Biochemicals &
Krebs Biochemicals & Industries Limited manufactures and sells active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry fields. Its products, such as androstenedione, lovastatin, and simvastatin for anti-cholesterol and steroid intermediate applications. The company is also developing various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. Krebs Biochemicals & Industries Limited was incorporated in 1991 and is headquartered in Hyderabad, India.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators